Corsens® is a platform technology that measures, displays and reports electromagnetic fluctuations generated by the activity of the heart.

Creavo’s first product to market, Corsens®, will enable healthcare professionals to use the device as an aid to rapidly and accurately rule out patients attending the emergency department with symptoms consistent with those of acute coronary syndrome.


Corsens® is a platform technology that measures, displays and reports electromagnetic fluctuations generated by the activity of the heart.

Creavo’s first product to market, Corsens®, will enable healthcare professionals to use the device as an aid to rapidly and accurately rule out patients attending the emergency department with symptoms consistent with those of acute coronary syndrome.


Corsens® is a platform technology that measures, displays and reports electromagnetic fluctuations generated by the activity of the heart.

Creavo’s first product to market, Corsens®, will enable healthcare professionals to use the device as an aid to rapidly and accurately rule out patients attending the emergency department with symptoms consistent with those of acute coronary syndrome.

*For investigational use only, not approved for sale

Corsens® an aid to rule out

A majority of patients presenting to emergency departments with chest pain do not get diagnosed with acute coronary syndrome2. However, most will still follow the extensive chest pain pathway – increasing pressure on already strained clinical resources. With Corsens®, healthcare professionals can utilise the MCG results as an aid to rule out active ischaemia in patients presenting with symptoms consistent with those of acute coronary syndrome and direct them to the most appropriate care pathway.

This is achieved by detecting distortions in the heart’s magnetic field caused by the presence of ischaemic (lacking oxygen) or necrotic (dead) cells which can be clearly observed in the resulting MCG field map and trace score.

2 Backus et al. 2011; Rohacek et al. 2012; Six et al. 2012; Backus et al. 2013

Clear user-friendly interface

Healthcare professionals require quick, accurate information to be presented in a clear and easily-digestible format. Corsens® features a simple touchscreen interface, with a clear graphic data display that can be used by healthcare professionals with very little additional training to that needed to perform a routine ECG.

Clear user-friendly interface

Healthcare professionals require quick, accurate information to be presented in a clear and easily-digestible format. Corsens® features a simple touchscreen interface, with a clear graphic data display that can be used by healthcare professionals with very little additional training to that needed to perform a routine ECG.

Designed to work in your world

Corsens® has been designed to negotiate busy emergency departments and be used with ease at the patient’s bedside. Designed with the input of healthcare professionals, Corsens® ensures that the diagnostic value of MCG can be utilised in the initial triage of patients presenting to the emergency department with symptoms consistent with those of acute coronary syndrome.

The device can be deployed to the patient’s bedside where the sensor head is positioned over the patient’s chest. The test is entirely non-invasive, passive and can be performed through clothing. Relatives and those supporting the patient can be present through the entire procedure. Reports can be reviewed on the device or on an optional external workstation.

Once completed, the scan head can be re-stowed and the device moved from the immediate clinical area to allow patient care to continue.

Designed to work
in your world

Corsens® has been designed to negotiate busy emergency departments and be used with ease at the patient’s bedside. Designed with the input of healthcare professionals, Corsens® ensures that the diagnostic value of MCG can be utilised in the initial triage of patients presenting to the emergency department with symptoms consistent with those of acute coronary syndrome.

The device can be deployed to the patient’s bedside where the sensor head is positioned over the patient’s chest. The test is entirely non-invasive, passive and can be performed through clothing. Relatives and those supporting the patient can be present through the entire procedure. Reports can be reviewed on the device or on an optional external workstation.

Once completed, the scan head can be re-stowed and the device moved from the immediate clinical area to allow patient care to continue.

Practical design

1. Easy to use
Testing is completely passive and requires very little training to perform, allowing healthcare professionals to spend time with their patient, rather than waiting for specialist operators.

2. Rapid Results
The device provides a result within a few minutes which has a high negative predictive value when used in conjunction with a risk assessment protocol to help identify non-cardiac patients early in the triage process.

3. Point of care
The device can be deployed straight to a patient’s bedside at the point of care, without the need for dedicated fixed locations or liquid helium cooling.

Are you interested in seeing Corsens® in action?

Are you interested in seeing Corsens® in action?

Other clinical applications

Ischaemia

Myocardial ischaemia is a condition where blood flow to the heart is reduced. This causes a lack of oxygen which can lead to a ‘heart attack’. Corsens® aids healthcare professionals in ruling out active Ischaemia in patients presenting with symptoms consistent with those of acute coronary syndrome in the emergency department.

Arrhythmia

Arrhythmia is a disruption of the heart’s normal, regular rhythm. Some arrhythmias, particularly those associated with coronary heart disease, may be life threatening and result in sudden cardiac death (SCD). SCD, both in patients with known risk factors and in people who have had no previous symptoms, is a major public health problem. MCG has the potential to help researchers, and ultimately clinicians, identify those most at risk of SCD, resulting in appropriate, life saving treatments. MCG may also prove useful in helping to identify patients most likely to benefit from expensive treatments for both arrhythmias and severe heart failure.

Distributors

Creavo are looking to expand our range of global partners, particularly as we continue grow our business around the world. If you are interested in partnering with us, we’d like to hear from you.

Frequently Asked Questions

Frequently Asked Questions

Who is Creavo Medical Technologies Ltd and who is behind it?

Creavo Medical Technologies Ltd is a UK-based, privately held medical device company that is developing innovative diagnostic technologies.

The company was formed to bring to market the innovative technology developed by Professor Ben Varcoe, Chair of Quantum Information Science at the University of Leeds and has facilities in Leeds, Coventry UK and a US office in Boston MA.

Creavo Medical Technologies has an experienced management team, with a mix of research, medical device, manufacturing, global regulatory and clinical strategy specialists.

How much time and money do you anticipate Corsens® could save hospitals?

Based on published literature, it is estimated that up to 70% of patients who present at the emergency department with chest pain have a non-cardiac condition3, but many of these will still go through the complete cardiac triage process which can take many hours. Therefore, identifying a non-cardiac patient early can save a hospital hundreds of pounds per patient. In addition, for inpatients who have had or are having a heart-related problem, it has been proven in various studies that the longer a patient waits for treatment following the onset of chest pain the worse their eventual outcome will be. The device could save a healthcare systems millions of pounds per year.

3 Backus et al. 2011; Rohacek et al. 2012; Six et al. 2012; Backus et al. 2013

What clinical trials have been undertaken so far and what are the outcomes?

A large, multi-centre study is in progress at five of the UK’s NIHR emergency departments (Sheffield Teaching Hospitals NHS Foundation Trust, University Hospitals of Leicester NHS Trust, North Bristol NHS Trust, Nottingham University Hospitals NHS Trust and St Georges Healthcare NHS Trust). This represents the largest ever clinical study with a magnetocardiography device, and results are due for publication in 2019.

Two smaller clinical trials have been performed at Leeds General Infirmary, led by Professor Mark Kearney, University of Leeds and British Heart Foundation Professor of Cardiology. The first was in 2014 and involved 120 patients (60 who were attending chest pain clinic and 60 ‘normal’ with no cardiac conditions) – each person had four scans over a period of a few days. These data were used to help understand how the device could be used to aid rule out in the emergency department. The second study involved 40 patients (20 with confirmed heart attacks and 20 confirmed clear). Data from both initial sets of clinical trials indicate that Corsens® could rule out a significant percentage of patients who would ultimately be diagnosed as having no cardiac condition (in emergency departments this would be done at initial triage). At present, all tests are rule-in tests so a patient that ultimately does not have a cardiac condition (a ‘normal’ patient) has to have all of the tests and fail them by a process of elimination to show that they do not have a heart condition. This essentially means that the people who do not have a heart problem experience some of the longest hospital stays – a rule out test detects ‘normality’ first.

A major, multi-centre study is also underway at major medical centres in the US – the country’s largest ever magnetocardiography study.